Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19
- PMID: 32283154
- PMCID: PMC7151471
- DOI: 10.1016/j.jinf.2020.03.044
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19
Conflict of interest statement
Declaration of Competing Interest We declare no competing interests.
Figures
Comment on
-
Coronavirus 2019-nCoV: A brief perspective from the front line.J Infect. 2020 Apr;80(4):373-377. doi: 10.1016/j.jinf.2020.02.010. Epub 2020 Feb 25. J Infect. 2020. PMID: 32109444 Free PMC article. Review.
References
-
- Yang Xiaobo, Yu Yuan, Xu Jiqian. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,retrospective, observational study. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30079-5. Published OnlineFebruary 21, 2020. - DOI - PMC - PubMed
-
- Ivan F.N, Hung Hyperimmune IV Immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464–473. - PubMed
-
- Takashi T, Hiroki M, Kiyohide F. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Diseases. 2015;61(3):385–392. - PubMed
-
- Diebel LN, Liberati DM, Diglio CA. Immunoglobulin a modulates inflammatory responses in an in vitro model of pneumonia. J Trauma Injury Infect Crit Care. 2005:1099–1106. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical